Fc glycoengineering services are provided to alter the N-linked glycosylation on the Fc portion of antibodies to increase or decrease a therapeutic antibody's affinity for different Fc gamma receptors and complement proteins. Changing therapeutic antibodies glycosylation can tune their effector function. The service package offers cell line engineering, enzymatic glycosylation remodeling, and both upstream and downstream processing to generate antibodies featuring specific glycoforms that boost ADCC, ADCP, and CDC, or to eliminate effector function, particularly for immune checkpoint inhibitors.
Fc glycosylation has been shown to modify antibody effector function by structural confirmation and affinity towards Fc gamma receptors as well as immune complexes. This property is desired because it determines if an antibody therapeutic will produce the appropriate functional response. Antibody Fc region is defined as the part of the antibody comprised of the constant regions that interact with Fc gamma receptors and complement proteins to mediate immune effector functions. When we look at the structure of the Fc region we see that it consists of a homodimer linked by a conserved N-linked glycosylation to asparagine 297 (Cdomain). Adequate Fc glycosylation allows for stabilization of the Fc fragment in its active confirmation enabling it to bind to immune receptors. Modifications to N297 glycans produced changes in immunogenicity and PK properties that were glycoform specific. This highlights the need for control of glycosylation during production in order to reduce batch-to-batch variability. Additionally, with the continuous development of novel antibody therapeutics there is a need for specialized modification to antibody effector functions. Some mechanisms currently being developed include enhancement of cellular cytotoxicity for cancer therapy antibodies and inhibition for antibody-directed enzyme prodrug therapy (ADEPT). Therefore, there is a developing demand for glycoengineering technologies that can tailor make Fc glycosylation to each desired mechanism of action.
Table 1 Impact of Fc Glycosylation on Antibody Effector Functions
| Glycan Feature | Effector Function Impact | Biological Consequence | Therapeutic Consideration |
| Core fucose absence | Enhanced FcγRIIIa binding | Increased ADCC activity | Desirable for oncology indications |
| High galactose content | Enhanced C1q binding | Increased CDC activity | Beneficial for complement-mediated killing |
| Sialic acid presence | Reduced FcγRIIIa affinity | Decreased ADCC; potential anti-inflammatory activity | Context-dependent benefit |
| High mannose structures | Altered FcγR binding; rapid clearance | Modified effector function; reduced half-life | Generally undesirable for most therapeutics |
| Bisecting GlcNAc | Enhanced FcγRIIIa binding | Increased ADCC without complement activation | Favorable for selective effector enhancement |
Mechanistically, Fc glycoengineering seeks to understand how each sugar affects immune cell activation. This requires examination of structural glycobiology and immunology principles including how different glycans modulate binding to Fc gamma receptors (FcγRs) and complement and structural studies detailing how the N-glycan on Asn297 locks Fc into its conformation and participates in some receptor engagements. Modifying glycans allows us to correlate structure and function, allowing for the customization of antibodies.
Table 2 Structural Features of Fc N-Glycans and Their Functional Implications
| Glycan Structural Element | Conformational Role | Effector Function Impact |
| Core heptasaccharide | Maintains C′E loop stability | Baseline Fc receptor accessibility |
| Terminal galactose | Extends glycan reach toward C1q | Enhanced complement activation |
| Core fucose residue | Restricts C′E loop mobility | Reduced FcγRIIIa affinity |
| Bisecting GlcNAc | Alters glycan orientation | Selective effector potentiation |
| Sialic acid capping | Modulates overall charge | Modified inflammatory signaling |
There is one site for N-glycosylation in the Fc region, at asparagine residue N297 in the Cdomain. The attached oligosaccharide is of complex type. This biantennary core glycan includes a heptasaccharide core of two N-acetylglucosamine (GlcNAc) residues and three mannose residues with further galactose, sialic acid, fucose, and bisecting GlcNAc residues potentially attached. Differences in processing yield heterogeneity in glycan species present from high-mannose to terminally modified complex glycans. Terminal sugars alter the positioning of the glycan on the protein. Attachment of galactose and sialic acid elongate the glycan away from the protein whereas core fucosylation and bisecting GlcNAc impact glycan positioning by introducing steric bulk. Variations in glycosylation can alter the exposure of the C′E loop and surrounding regions that form the Fc receptor contact area.
ADCC is likely the dominant effector function of therapeutic antibodies resulting in NK cell-mediated killing through binding of FcγRIIIa and subsequent NK cell degranulation. The ADCC pathway involves secretion of lytic granules that induce apoptosis in the target cell. CDC involves binding of antibody-bound C1q leading to activation of the classical complement cascade. This results in formation of membrane damaging pores as well as inflammatory mediators called anaphylatoxins. Antibody-dependent cellular phagocytosis results in activation of macrophages and monocytes through engagement of FcγRIIa. This leads to phagocytosis and lysosomal degradation of target cells opsonized by antibodies. Macrophages activated through FcγRIIa may also show increased antigen presentation. Effector functions that result in anti-inflammatory signaling result through binding to FcγRIIb or glycan receptors. Specifically, increased sialylation of IgG antibodies has been shown to induce anti-inflammatory signaling pathways. Fc effector functions happen via distinct and at times overlapping pathways. Glycosylation of the Fc fragment alters affinity for different receptors which can skew the antibody towards unique effector functions. This understanding allows for manipulation of the Fc glycome for use in treatments that require more aggressive targeting of cancer cells or induction of tolerance.
mAb structure and mechanisms of action.1,5
Fc glycans directly contact and modulate interactions with Fcγ receptors. Glycan mediated modulation of Fcγ receptor binding occurs by both physical means and indirect means by affecting conformation of the Fc fragment as glycans can sterically block residues important for Fcγ receptor contact. For example, core fucosylation decreases flexibility of the C′E loop, causing steric clash with carbohydrates on FcγRIIIa and decreasing binding. Additionally, the lack of core fucose allows more flexibility in conformation and the ability for additional carbohydrate-carbohydrate contacts between Fc glycans and FcγRIIIa glycans, which increases affinity for activating FcγRs. Changes in terminal galactosylation can alter charge or structure of the glycan depending on the nature of the modification. Increased galactosylation correlates with increased binding to FcγRIIIa whereas increased sialylation of Fc glycans caps the glycan with negative charges which ablates binding to most activating FcγRs but may increase binding to inhibitory or Ig-like FcγRs. Addition of bisecting GlcNAc changes the angle of the glycan away from the anti-parallel β-sheet and increases ADCC without significantly affecting complement activation. Both direct and indirect glycan effects on FcγRs also work with the protein backbone to affect thermodynamics and kinetics of immune complex formation.
Services include all aspects of antibody glycoengineering. Modifications to the Fc glycosylation of antibodies can be made using engineered cell lines or ex vivo enzymatic remodeling. Services range from host cell engineering all the way to process development and control. This includes characterization and development of antibody production cell lines with desired glycoform profiles. Glycoengineering services are useful for both discovery of lead candidates, as well as for commercial scale production.
The first main approach of antibody optimization is called controlled afucosylation. This has mostly consisted of removal of core fucose to increase ADCC. Deletion of α-1,6-fucosyltransferase or inhibition of GDP-fucose is one way to accomplish the lack of core fucose on antibodies. The resulting lack of fucose enables improved binding to FcγRIIIa on NK cells. Increased galactosylation has also been used to increase antibody affinity for binding to the complement protein C1q and therefore increase CDC. This can be accomplished by over expression of β-1,4-galactosyltransferase or increasing donor substrate availability for terminal addition of galose. Manipulation of antibody sialylation has also been used to induce anti-inflammatory characteristics while increasing serum half-life. Overexpression of α-2,6-sialyltransferase and control of available substrate can help achieve increased capping. Minimizing macroheterogeneity of antibody glycans by reducing levels of aglycosylated heavy chains and high mannose type glycans can be accomplished through careful control of ER quality control checkpoints and Golgi exit. Any of these methods can be used alone or in various combinations to yield antibodies with desired glycoform content. For example, antibodies designed to target cancer may benefit from afucosylation and increased galactosylation to increase their ability to elicit effector function. Antibodies designed to treat autoimmune diseases may benefit from increased sialylation.
CHO cells are the most widely used expression host for recombinant antibody manufacturing and can be engineered at the genome level using programmable nucleases such as CRISPR. Specific genes involved in glycosylation can be knocked out, or "switched on" using systems that activate transcription of specific genes. In addition to manipulating individual genes, synthetic biologists can also engineer the larger glycosyltransferase network by controlling nucleotide sugar levels and localization of processing enzymes within the Golgi. To achieve this, metabolic pathways are engineered to increase or decrease intracellular sugar nucleotide levels by overexpressing or knocking down sugar transporters and sugar nucleotide biosynthesis enzymes. Genetic systems can also be used to rapidly screen for glycosylation phenotypes of interest (such as using lectin-based screening methods to identify clones with desired glycosylation profiles from a pool of engineered cells), and create cell lines that faithfully produce antibodies with customized glycans that are stable for prolonged periods of time and through scale-up processes.
Enzymatic remodeling after protein expression is an orthogonal strategy to cell engineering to produce specific glycoforms. This can be especially useful for tweaking already existing antibody candidates or performing high-throughput screens of glycoforms during lead selection. Treating with Endo H truncates mixed natural glycans to a single GlcNAc, which acts as a substrate for transglycosylation with activated sugar oxazolines in the presence of glycosynthase enzymes. This allows for the addition of defined non-fucosylated, galactosylated, or sialylated glycans to antibodies regardless of the glycosylation machinery of the cell of origin. Because remodeling can be done quickly as a proof-of-concept, one can functionally test multiple glycoforms made from the same bulk parent material. Therefore, glycoform REMS can speed up SAR without the need to develop multiple cell lines. Targeted glycoengineering techniques can selectively modify isolated glycosylation sites by removing glycans with site-specific deglycosidases followed by reglycosylation of the protein with defined homogeneous glycans. This allows for homogeneous glycosylation at specific sites that can be challenging to achieve with cell engineering techniques alone. These techniques act as an adjunct to cell-based technologies, allowing for additional flexibility in late-stage selection as well as generation of specialized glycoforms for mechanistic investigations or comparative clinical studies.
During bioprocess development, conditions are developed to make the glycan profile of a product consistent between scaled up manufacturing processes, from discovery phase laboratory scale to commercial production scale. Media development affects glycosylation through adjustments to nutrient availability, including addition of exogenous sugars or nucleotide sugars, nucleotide donors and metal ions which affect the activity of glycosyltransferases and the availability of sugar donors. Control of bioprocess parameters like temperature, pH, dissolved oxygen, and osmolality over the course of the culture can affect the processing capacity of the Golgi and thereby affect glycoform outcome. Characterization of mixing times and oxygen transfer limitations at production scale ensures that cells have the ability to glycosylate effectively at larger scales. Process monitoring can be used to assess glycosylation intermediates as well as product glycoforms so that process adjustments can be made in real time if raw material changes or equipment performance cause glycoform variation outside of specifications. Glycan critical quality attributes (CQAs) are established during development and used to build quality-by-design (QbD) models that establish a design space where process parameters can vary but CQAs will still be met for commercial production.
Fc glycoengineering can be applied to different therapeutic antibody formats, as adjustment of antibody effector function through glycoengineering can be rationalized to fit the disease state. Antibody-based therapeutics can be glycoengineered to increase killing activity for oncology applications, decrease inflammation for autoimmune diseases, or maximize efficacy of payload release for antibody-drug conjugates (ADCs). Since altering the glycan on the Fc domain changes the interaction of a given antibody with immune receptors and complement, glycoengineering allows for the same antibody format to be used for entirely different mechanisms of action.
Afucosylation is the most common engineering modification used to enhance ADCC in therapeutic antibodies. By removing the core fucose from the Fc N-glycan, engineered antibodies are relieved from the steric clash that prevents FcγRIIIa on NK cells and macrophages from interacting with its optimal angle. This change allows for greater mobility of the C′E loop region on Cdomain to allow favorable C-C interactions that dramatically improve interactions with activating FcγRs. This antibody engineering strategy has been found useful in improving antibody therapies against leukemias in which tumor cells display antigens on the surface of cancer cells and can be targeted by antibodies, as well as solid tumors where potent cellular cytotoxicity may work synergistically with antibody-mediated signaling blockade. Antibodies with afucosylated glycans are able to bind weakly expressed alleles of FcγRIIIa, creating universal antibodies effective for individuals of different genetic backgrounds. Antibodies lacking core fucose show enhanced ability to recruit immune cells which leads to improved killing of target cells via NK cell degranulation and macrophage phagocytosis. Afucosylation has been applied to a variety of therapeutic antibodies and has been shown to increase response rate and progression free survival. Afucosylated antibody products can be produced either through cell line engineering or through enzymatic remodeling of therapeutic antibodies to homogeneous afucosylated forms.
Terminal galactosylation of Fc N-glycans is considered the major determinant of Fc-mediated CDC. Complement proteins are rapidly recruited and activated upon antibody binding to their target antigens. Galactose residues complete formation of the hexameric IgG structure necessary for high affinity binding to the C1q portion of the classical complement cascade, which results in formation of the membrane attack complex and pro-inflammatory cytokines known as anaphylatoxins. Increasing levels of galactosylation on antibodies increases CDC activity by promoting greater interaction with the classical complement cascade. This property can be harnessed when antibodies are intended to target cell surface antigens on complement susceptible cells. For example, if the complement system is available in the tumor microenvironment and is desired to aid in direct cell killing, terminal galactosylation can be increased to enhance CDC activity of the antibody. However, if CDC potency would lead to anti-drug antibody development or other safety concerns, removal of terminal galactose or addition of terminal sialic acid can prevent binding to C1q, thus decreasing CDC potency. This selective manipulation allows for antibodies with higher or lower affinity for recruiting the complement system depending on the mechanism of action needed for treating a particular disease. Targeting cell surface antigens with the ability to modulate CDC independently from ADCC allows for more precise engineering of antibodies for specific tumor microenvironments.
Increasing alpha-2,6-linked sialic acid on Fc N-glycans is the first known method to develop anti-inflammatory antibodies. Anti-inflammatory IgGs have been shown to interact with immune-regulatory pathways that silence inflammatory immune responses through selective alteration of their Fc receptor binding. These antibodies have decreased affinity to activating FcγRs while still binding inhibitory FcγRIIb. Sialic acid addition changes the orientation of Cdomains in Fc regions, thus changes how the domains interact with the Fc receptor and immune cell signaling.
Anti-inflammatory antibodies are ideal candidates for IVIG preparations as well as therapeutics used to treat patients with autoimmune diseases because many of these diseases are exacerbated by inflammation rather than provoked by a lack of cytotoxic activity. In addition to blocking activating Fc receptors, anti-inflammatory antibodies can actively silence immune cells. These antibodies have therapeutic potential in diseases such as immune thrombocytopenia, RA, and other inflammatory diseases. Therapeutics with these glycan properties have also been shown to interact with dendritic cells and induce regulatory T cell generation. These findings suggest that antibodies with anti-inflammatory glycans have potential to be used in many tolerogenic therapies. Fully-sialylated antibodies have been engineered and shown to have anti-inflammatory properties in disease models. These antibodies can be made through chemoenzymatic synthesis. In order to produce these antibodies with increased anti-inflammatory activity, the expression and addition of glycosyltransferases and sugar donors must be tightly regulated to ensure complete capping of the terminal sugar.
The rationale for Fc glycoengineering of ADCs stems from coupling of their main mechanism of action with maintained or tweaked Fc effector functions. ADCs function predominantly through antibody-targeted delivery and intracellular release of highly cytotoxic drugs. However, maintained effector function allows additional killing of target cells as well as neighboring antigen-negative cells through bystander killing. Removal of fucose from an ADC's Fc region maintains ADC ADCC functionality. This may help with killing of tumor cells that did not receive enough drug to be killed by the delivered payload. Antibody-targeted delivery is important in overcoming heterogeneity and resistance within tumors. Engineering glycans on ADCs has also been used as a tool to achieve site-specific drug conjugation while maintaining structural integrity of the Fc and its effector functions. Site-specific conjugation also allows for more homogeneous drug-antibody ratios. The addition of effector function allows for therapeutics with a dual mechanism of action. In this case, antibody-targeted delivery of toxic drugs works alongside immune cell recruitment. Effector functions such as ADCC may be tuned to not interfere with the potent cytotoxic agents being delivered to the target cell. Considerations for glycoengineering an ADC include potency of the cytotoxic drug being delivered and the desired effect from antibody effector functions. As with traditional ADCs, glycoengineered variants require process development to maintain integrity of the antibody as well as drug. Homogenous glycoforms allow for ease of manufacture and predictable behavior of the drug.
Illustration of the relevant effector functions of approved therapeutic antibodies.2,5
Optimizing Fc glycosylation to precisely modulate antibody effector function requires deep scientific insight, robust analytical infrastructure, and a development strategy aligned with regulatory expectations. Our Fc glycoengineering services integrate advanced cell line engineering, glycan remodeling technologies, and functional validation platforms to help you achieve predictable, scalable, and development-ready outcomes. From early discovery through IND-enabling studies, we provide data-driven solutions designed to reduce risk and accelerate progress.
Effective Fc glycoengineering goes beyond altering glycan structures—it requires direct correlation between glycan profiles and biological function. Our integrated platform combines molecular engineering with orthogonal analytical and biofunctional validation to ensure measurable improvements in effector activity.
By integrating glycan engineering with functional assays, we establish clear structure-function relationships that support both scientific rigor and regulatory documentation.
Our Fc glycoengineering services are designed to support antibody programs across the full development continuum. We align glycan optimization strategies with your molecule's mechanism of action, target indication, and development milestones.
This integrated approach minimizes translational gaps between discovery research and clinical manufacturing readiness.
Every therapeutic antibody requires a tailored balance of effector mechanisms. Whether the goal is to enhance cytotoxic activity, modulate complement activation, or reduce inflammatory signaling, our Fc glycoengineering strategies are customized to your program's specific objectives.
Our data-driven optimization ensures that Fc modifications are strategically aligned with therapeutic intent, safety considerations, and pharmacokinetic requirements.
Fc glycosylation is recognized as a critical quality attribute in biologics development. We implement scalable engineering and control strategies that withstand regulatory scrutiny and support long-term manufacturing consistency.
Our focus is not only on optimizing effector function but on delivering a development-ready Fc glycoengineering solution that supports clinical progression and commercial success.
References
